Press Release

Newcastle, U.K. - October 13, 2011

QuantuMDx Group Limited today announced that it has signed an exclusive license agreement with Nanosys Inc., an advanced materials architect, for several patents and patent applications related to the use of nanostructures for biosensors.

The core intellectual property involves the use of nanowire and nanotubes in biosensors, including field effect transistors (FETs) biosensors, which were derived from the work of Prof. Charles Lieber, a professor of chemistry at Harvard, pioneer in nanotechnology, and one of the founders of Nanosys.

Under terms of the agreement, QuantuMDx Group has secured exclusive worldwide rights for the use of nanostructures for DNA sequencing and, amongst others, detecting nucleic acid biomarkers associated with disease. In exchange, Nanosys has received an upfront license fee and downstream royalty payments. No other financial details of the deal were disclosed.

Nanosys owns an extensive IP portfolio around multiple aspects of nanotechnology including quantum dots and nanowires for diverse applications, with a primary focus on LED backlighting and energy storage. QuantuMDx Group will use the exclusive access to these nanowire composition, synthesis and use patents, along with its proprietary molecular biology, chemistry and microfluidic technologies in a series of portable devices for molecular diagnostics and DNA Sequencing. The power of Nanosys’ technology is that it enables accurate diagnosis and quantification of multiple biomarkers using small arrays of biosensors that readily lends itself to “DNA sequencing while you wait” diagnostic devices with numerous medical, veterinary and military applications.

"Rapid and sensitive disease detection and DNA identification, performed at the point of care, at an affordable price point and to standards usually only seen in the referral laboratory will revolutionize care pathways in the developed world and open up a whole new standard of diagnosis in third world nations” said Elaine Warburton, chief executive officer of QuantuMDx Group. “QuantuMDx Group is meeting this global health challenge and is currently developing several low cost assays on our hand-held point of care device including multi-drug resistant infectious disease testing and companion diagnostics for accurate drug prescription."

QuantuMDx Group’s medical director, Professor Sir John Burn, went on to say "We are creating a simple to use, sample to result device which will provide robust, handheld, clinical DNA sequencing at the point of care. The technology is cheap by any measure and with turnaround times in the minutes, it will be an exciting and significant new instrument in the clinical tool box. I believe it will facilitate the wider uptake of DNA sequencing by the medical fraternity."

Andrew Filler, general counsel and vice president of intellectual property at Nanosys, commented, "We are pleased that QuantuMDx Group has chosen to become our exclusive licensee of our broad and deep intellectual property around nanowires for biosensor devices. Through continued development.

Download this press release

About QuantuMDx Group Limited

QuantuMDx Group is a U.K. based nanomedtech company founded by Elaine Warburton, an experienced healthcare chief executive and Jonathan O’Halloran, a molecular biologist and the inventor of QuantuMDx Group’s technology. QuantuMDx Group is developing and commercializing affordable handheld sample-to-resultlicensing and commercialization efforts, Nanosys is expanding the transformative applications of advanced the marketplace. diagnostic and genomic sequencing technologies based around a nanowire biosensor and innovative microfluidics. The company has offices in the U.K. and U.S.A.. Additional information on QuantuMDx Group can be found at www.quantumdx.com

About Nanosys, Inc.

Nanosys, Inc. is an advanced material architect, harnessing the fundamental properties of inorganic materials into process ready systems that can integrate into existing manufacturing to produce vastly superior products in lighting, electronic displays and energy storage.. Based in Palo Alto, Nanosys has built one of the broadest technology platforms in the industry with over 750 patents and patent applications covering fundamental areas of nanotechnology. Additional information on Nanosys can be found at www.nanosysinc.com.

For Further Information:

QuantuMDx Contact:
Elaine Warburton, chief executive officer
Tel: +44 791 22 06 106
Email: elaine.warburton@quantumdx.com

Nanosys Contact:
Andrew Filler, general counsel and vice president of intellectual property
Tel. +1 (650) 331-2176
Email: afiller@nanosysinc.com

Back to News